Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Saved in:
| Title: | Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. |
|---|---|
| Authors: | Michelakos T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Cai L; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China., Villani V; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Sabbatino F; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Kontos F; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Fernández-Del Castillo C; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Yamada T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Neyaz A; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Taylor MS; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Kurokawa T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ting DT; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Qadan M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Weekes CD; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Allen JN; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Clark JW; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ryan DP; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Warshaw AL; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lillemoe KD; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ferrone CR; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. |
| Source: | Journal of the National Cancer Institute [J Natl Cancer Inst] 2021 Feb 01; Vol. 113 (2), pp. 182-191. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1460-2105 |
|---|---|
| DOI: | 10.1093/jnci/djaa073 |
